Molecular mechanisms of action of bisphosphonates

Bone

Volumn 24, Issue 5 SUPPL., 1999, Pages 73S-79S

  Rogers, M J ^a   Frith, J C ^a,b   Luckman, S P ^a,b   Coxon, F P ^a,b   Benford, H L ^a   Monkkonen J ^c   Auriola, S ^c   Chilton, K M ^b   Russell, R G G ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; IBANDRONIC ACID; INCADRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; BONE MINERAL; BONE MINERALIZATION; CALCIFICATION; HUMAN; IN VITRO STUDY; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRENYLATION; REVIEW; STRUCTURE ACTIVITY RELATION;

EID: 0032929644     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/S8756-3282(99)00070-8     Document Type: Article

References (69)

1. Adami S., Bhalla A.K., Dorizzi R., Montesanti F., Rosini S., Salvagno G., Lo Cascio V. The acute phase response after bisphosponate administration. Calcif Tissue Int. 41:1987;326-331.
2. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G.E., Perrone M.H. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res. 33:1992;1657-1663.
3. Amin D., Cornell S.A., Perrone M.H., Bilder G.E. 1-hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res. 46:1996;759-762.
4. Auriola S., Frith J., Rogers M.J., Koivuniemi A., Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chromatogr B. 704:1997;187-195.
5. Azuma Y., Sato H., Oue Y., Okabe K., Ohta T., Tsuchimoto M., Kiyoki M. Alendronate distribution on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone. 16:1995;235-245.
6. Boonekamp P.M., van der Wee-Pals L.J.A., van Wijk-van Lennep M.L.L., Wil Thesing C., Bijvoet O.L.M. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1:1986;27-39.
7. Carano A., Teitelbaum S.A., Konsek J.D., Schlesinger P.H., Blair H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 85:1990;456-461.
8. + ATPase. J Bone Miner Res. 11:1996;1498-1507.
9. Delmas P.D., Meunier P.J. The management of Paget's disease of bone. N Engl J Med. 336:1997;558-566.
10. Ebetino F.H., Bayless A.V., Amburgey J., Ibbotson K.J., Dansereau S., Ebrahimpour A. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphor Sulfur Silicon. 109/110:1996;217-220.
11. Ebrahimpour A., Francis M.D. Bisphosphonate therapy in acute and chronic bone loss Physical chemical considerations in bisphosphonate-related therapies . Bijvoet O., Fleisch H.A., Canfield R.E., Russell R.G.G. Bisphosphonate on Bones. 1995;Elsevier, Amsterdam.
12. Endo N., Rutledge S.J., Opas E.E., Vogel R., Rodan G.A., Schmidt A. Human protein tyrosine phosphatase-σ Alternative splicing and inhibition by bisphosphonates . J Bone Miner Res. 11:1996;535-543.
13. Felix R., Russell R.G.G., Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta. 429:1976;429-438.
14. 2MBP-coated bone. Bone Miner. 6:1989;33-43.
15. Fleisch H. Bisphosphonates, pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs. 42:1991;919-942.
16. Fleisch H.A., Russell R.G.G., Bisaz S., Muhlbauer R.C., Williams D.A. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest. 1:1970;12-18.
17. Fleisch H., Russell R.G.G., Francis M.D. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 165:1969;1262-1264.
18. Fleisch H., Russell R.G.G., Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 212:1966;901-903.
19. Frith J.C., Mönkkönen J., Blackburn G.M., Russell R.G.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-β,γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res. 12:1997;1358-1367.
20. Geddes A.D., D'Souza S.M., Ebetino F.H., Ibbotson K.J. Bisphosphonates Structure-activity relationships and therapeutic implications . Bone Miner Res. 8:1994;265-306.
21. Hughes D.E., MacDonald B.R., Russell R.G.G., Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 83:1989;1930-1935.
22. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., Mundy G.R., Boyce B.F. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 10:1995;1478-1487.
23. Lerner U.H., Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis and mitotic activities in mouse calvarial bones in vitro. Bone. 8:1987;179-189.
24. Liberman U.A., Weiss S.R., Broll J., Minne H.W., Quan H., Bell N.H., Rodriquez-Portales J., Downs R.W., Dequeker J., Favus M., Seeman E., Recker R.R., Capizzi T., Santora A.C., Lombardi A., Shah R.V., Hirsch L.J., Karpf D.B. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med. 333:1995;1437-1443.
25. Löwik C.W.G.M., van der Pluijm G., van der Wee-Pals L.J.A., Bloys van Treslong-de Groot H., Bijvoet O.L.M. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts the effect of a bisphosphonate . J Bone Miner Res. 3:1998;185-192.
26. Luckman S.P., Coxon F.P., Ebetino F.H., Russell R.G.G., Rogers M.J. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation Evidence from structure-activity relationships in J774 macrophages . J Bone Miner Res. 13:1998;1668-1678.
27. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 13:1998;581-589.
28. Makkonen N., Hirvonen M.R., Teräväinen T., Savolainen K., Mönkkönen J. Different effects of three bisphosphonates on nitric oxide production by RAW 264 macrophage-like cells in vitro. J Pharmacol Exp Ther. 277:1996;1097-1102.
29. Marshall C. Protein prenylation A mediator of protein-protein interactions . Science. 259:1993;1865-1866.
30. Masarachia P., Weinreb M., Balena R., Rodan G.A. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. Bone. 19:1996;281-290.
31. Mönkkönen J., Similä J., Rogers M. Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci. 62:1998;95-102.
32. Murakami H., Takahashi N., Sasaki T., Udagawa N., Tanaka S., Nakamura I., Zhang D., Barbier A., Suda T. A possible mechanism of the specific action of bisphosphonates on osteoclasts Tiludronate preferentially affects polarized osteoclasts having ruffled borders . Bone. 17:1995;137-144.
33. Murakami H., Takahashi N., Tanaka S., Nakamura I., Udagawa N., Nakajo S., Nakaya K., Abe M., Yuda Y., Konno F., Barbier A., Suda T. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 20:1997;399-404.
34. Nakamura M., Ando T., Abe M., Kumagai K., Endo Y. Contrast between effects of aminobisphosphonates and non-aminobisphosphonates on collagen-induced arthritis in mice. Br J Pharmacol. 119:1996;205-212.
35. Niskikawa M., Akatsu T., Katayama Y., Yasutomo Y., Kado S., Kugai N., Yamamoto M., Nagata N. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone. 18:1996;9-14.
36. Ohnuma S., Nakazawa T., Hemmi H., Hallberg A.-M., Koyama T., Ogura K., Nishino T. Conversion from farnesyl diphosphate synthase to geranylgeranyl diphosphate synthase by random chemical mutagenesis. J Biol Chem. 271:1996;10087-10095.
37. Olpas E.E., Rutledge S.J., Golub E., Stern A., Zimolo Z., Rodan G.A., Schmidt A. Alendronate inhibition of protein-tyrosine-phosphatase-Meg1. Biochem Pharmacol. 54:1997;721-727.
38. Papapoulos S.E., Hoekman K., Lowik C.W.G.M., Vermeij P., Bijvoet O.L.M. Application of an in vitro model and a clinical protocol in the assessment of the potentcy of a new bisphosphonate. J Bone Miner Res. 4:1988;775-781.
39. Pennanen N., Lapinjoki S., Urtti A., Mönkkönen J. Effect of liposomal and free bisphosphonates on the IL-1β, IL-6 and TNFα secretion from RAW264 cells in vitro. Pharm Res. 12:1995;916-922.
40. Ridley A.J., Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 70:1992;389-399.
41. Ridley A.J., Paterson H.F., Johnston C.L., Diekmann D., Hall A. The small GTP-binding protein rac regulates growth factor-induced membrane ruffling. Cell. 70:1992;401-410.
42. Rogers M.J., Brown R.J., Hodkin V., Russell R.G.G., Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun. 224:1996;863-869.
43. Rogers M.J., Chilton K.M., Coxon F., Lawry J., Smith M.O., Suri S., Russell R.G.G. Bisphosphonates induce apoptosis in mouse macrophage-like cells by a nitric-oxide-independent mechanism. J Bone Miner Res. 11:1996;1482-1491.
44. Rogers M.J., Ji X., Russell R.G.G., Blackburn G.M., Williamson M.P., Bayless A.V., Ebetino F.H., Watts D.J. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J. 303:1994;303-311.
45. Rogers M., Russell R.G.G., Blackburn G.M., Williamson M.P., Watts D.J. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun. 189:1992;414-423.
46. Rogers M.J., Watts D.J., Russell R.G.G., Ji X., Xiong X., Blackburn G.M., Bayless A., Ebetino F.H. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mould Dictyostelium discoideum. J Bone Miner Res. 9:1994;1029-1039.
47. Rogers M.J., Xiong X., Ji X., Mönkkönen J., Russell R.G.G., Blackburn G.M., Williamson M.P., Watts D.J. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res. 14:1997;625-630.
48. Russell R.G.G., Muhlbauer R.C., Bisaz S., Williams D.A., Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calc Tissue Res. 6:1970;183-196.
49. Sahni M., Guenther H., Fleisch H., Collin P., Martin T.J. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest. 91:1993;2004-2011.
50. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 5:1990;31-40.
51. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., Golub E., Rodan G.A. Bisphosphonate action. Alendronate localisation in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 88:1991;2095-2105.
52. Sauty A., Pecherstorfer M., Zimmerroth I., Fioroni P., Juillerat L., Markert M., Ludwig H., Leuenberger P., Burckhardt P., Thiebaud D. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonate treatment in vitro and in patients with malignancy. Bone. 18:1996;133-139.
53. Schenk R., Eggli P., Fleisch H., Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 38:1986;342-349.
54. 2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 11:1973;196-214.
55. Schmidt A., Rutledge S.J., Endo N., Opas E.E., Tanaka H., Wesolowski G., Leu C.T., Huang Z., Ramachandaran H., Rodan S.B., Rodan G.A. Alendronate inhibition of protein tyrosine phosphatase activity. Proc Natl Acad Sci. 93:1995;3068-3073.
56. Schweitzer D.H., Oostendorp-van de Ruit M., van der Pluijm G., Lowik C.W.G.M., Papapoulos S.E. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res. 10:1995;956-962.
57. Selander K.S., Mönkkönen J., Karhukorpi E.-K., Härkönen P., Hannuniemi R., Väänänen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol. 50:1996;1127-1138.
58. Shinoda H., Adamek G., Felix R., Fleisch H., Schenk R., Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 35:1983;87-99.
59. Shipman C.M., Rogers M.J., Apperley J.F., Russell R.G.G., Croucher P.I. Bisphosphonates induce apoptosis in human myeloma cell lines A novel anti-tumour activity . Br J Haematol. 98:1996;665-672.
60. Sietsema W.K., Ebetino F.H., Salvagno A.M., Bevan J.A. Antiresorptive dose-response relationships across three generations of bisphosphonates. Drugs Exp Clin Res. 15:1989;389-396.
61. Smith R., Russell R.G.G., Bishop M. Diphosphonate and Paget's disease of bone. Lancet. 1:1971;945-947.
62. Suda T., Nakamura I., Jimi E., Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 12:1997;869-879.
63. Van Beek E., Hoekstra M., Van der Ruit M., Löwik C., Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 9:1994;1875-1882.
64. Vitte C., Fleisch H., Guenther H.L. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology. 137:1996;2324-2333.
65. Yu X., Scholler J., Foged N.T. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106. Bone. 19:1996;339-345.
66. Zerial M., Stenmark H. Rab GTPases in vasicular transport. Curr Opin Cell Biol. 5:1993;613-620.
67. Zhang F.L., Casey P.J. Protein prenylation Molecular mechanisms and functional consequences . Annu Rev Biochem. 65:1996;241-269.
68. Zhang D., Udagawa N., Nakamura I., Murakami H., Saito S., Yamasaki K., Shibasaki Y., Morii N., Narumiya S., Takahashi N., Suda T. The small GTP-binding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci. 108:1995;2285-2292.
69. Zimolo Z., Wesolowski G., Rodan G.A. Acid extrusion is induced by osteoclast attachment to bone. J Clin Invest. 96:1995;2277-2283.